Document Detail


The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system.
MedLine Citation:
PMID:  1381795     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Factors that can influence cardiovascular growth are becoming increasingly important for our understanding of such complex diseases as cardiac hypertrophy, coronary artery disease, atherosclerosis, and hypertension. Several proto-oncogenes were found to be involved in the regulation of abnormal cell growth in cardiovascular disease. It is also evident that some peptide hormones, which are well known to be involved in blood pressure control, may play a role as growth modulators. Angiotensin II is one such peptide. It elevates blood pressure through its direct vasoconstrictor, sympathomimetic, and (through release of aldosterone) sodium-retaining activity but also appears to have mitogenic actions. Interestingly, all components of the renin-angiotensin system were found locally in cardiovascular tissues. The question remains whether angiotensin can act directly as a growth factor or whether it does so indirectly by influencing or modulating cell growth factors. A better understanding of the renin-angiotensin system as a direct or indirect mediator for cardiovascular hypertrophy would offer new and interesting insights into the pathophysiology of hypertension and possibly novel options for the treatment of cardiovascular disease.
Authors:
M Paul; D Ganten
Related Documents :
8505095 - Selective breeding to develop lines of baboons with high and low blood pressure.
7032775 - The relative roles of sodium and renin in the hypertension of renal disease. an assessm...
6986475 - The diagnostic and therapeutic uses of saralasin in renal transplant hypertension.
3780805 - A case of hypertension due to unilateral hydronephrosis in a child.
24728465 - Heterozygote loss of ace2 is sufficient to increase the susceptibility to heart disease.
16423855 - Differential effects of prenatal exposure to dexamethasone or cortisol on circulatory c...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  19 Suppl 5     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-10-15     Completed Date:  1992-10-15     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S51-8     Citation Subset:  IM    
Affiliation:
German Institute for High Blood Pressure Research, University of Heidelberg.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / pharmacology*
Animals
Blood Vessels / drug effects,  pathology*
Cardiomegaly / etiology*
Cell Division / drug effects
Cells, Cultured
Gene Expression
Growth Substances / physiology
Hypertension / physiopathology*
Hypertrophy / etiology
Muscle, Smooth, Vascular / cytology*,  drug effects
Proto-Oncogenes
Renin-Angiotensin System / physiology*
Chemical
Reg. No./Substance:
0/Growth Substances; 11128-99-7/Angiotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determining hypertensive end-organ damage in trials: a review of current methodologies and technique...
Next Document:  Hypertensive heart disease: pathophysiology and clinical and prognostic consequences.